A randomized, double-blind, placebo-controlled trial of duloxetine
in the treatment of women with fibromyalgia with or without major depressive disorder

by
Arnold LM, Rosen A, Pritchett YL, D'Souza DN,
Goldstein DJ, Iyengar S, Wernicke JF.
Women's Health Research Program,
Department of Psychiatry,
University of Cincinnati College of Medicine,
Medical Arts Building, 222 Piedmont Ave, Suite 8200,
Cincinnati, OH 45219, USA.
Pain. 2005 Dec;119(1-3):5-15.


ABSTRACT
This was a 12-week, randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of duloxetine, a selective serotonin and norepinephrine reuptake inhibitor, in 354 female patients with primary fibromyalgia, with or without current major depressive disorder. Patients (90% Caucasian; mean age, 49.6 years; 26% with current major depressive disorder) received duloxetine 60mg once daily (QD) (N=118), duloxetine 60mg twice daily (BID) (N=116), or placebo (N=120). The primary outcome was the Brief Pain Inventory average pain severity score. Response to treatment was defined as >/=30% reduction in this score. Compared with placebo, both duloxetine-treated groups improved significantly more (P<0.001) on the Brief Pain Inventory average pain severity score. A significantly higher percentage of duloxetine-treated patients had a decrease of >/=30% in this score (duloxetine 60mg QD (55%; P<0.001); duloxetine 60mg BID (54%; P=0.002); placebo (33%)). The treatment effect of duloxetine on pain reduction was independent of the effect on mood and the presence of major depressive disorder. Compared with patients on placebo, patients treated with duloxetine 60mg QD or duloxetine 60mg BID had significantly greater improvement in remaining Brief Pain Inventory pain severity and interference scores, Fibromyalgia Impact Questionnaire, Clinical Global Impression of Severity, Patient Global Impression of Improvement, and several quality-of-life measures. Both doses of duloxetine were safely administered and well tolerated. In conclusion, both duloxetine 60mg QD and duloxetine 60mg BID were effective and safe in the treatment of fibromyalgia in female patients with or without major depressive disorder.
Pain and depression
Withdrawal symptoms
Duloxetine (Cymbalta)
Duloxetine: efficacy and safety
Duloxetine for major depression
Duloxetine for urinary incontinence
Duloxetine: efficacy and tolerability
Duloxetine and painful physical symptoms
Duloxetine (Cymbalta, Xeristar): onset of action
Duloxetine (Cymbalta), serotonin and noradrenaline


Refs
and further reading

HOME
HedWeb
Nootropics
erythroxylum-coca.com
Future Opioids
BLTC Research
MDMA/Ecstasy
Superhapiness?
Utopian Surgery?
The Abolitionist Project
The Hedonistic Imperative
The Reproductive Revolution
Critique of Huxley's Brave New World

The Good Drug Guide
The Good Drug Guide

The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family